

ASX Announcement

28 October 2026

Results of 2026 Extraordinary General Meeting and Appointment of Director

Genetic Signatures Limited (ASX: GSS) advises that shareholders considered four resolutions at the Extraordinary General Meeting (EGM) held earlier today.

The EGM was convened following requisition notices received from BCAL Diagnostics Limited under section 249D of the Corporations Act 2001 (Cth).

Following the conduct of a poll on each resolution, shareholders approved Resolution 3, being the appointment of Mr John Robert Melki as a Director of the Company. Resolutions 1, 2 and 4 were not passed.

Accordingly, Mr Melki has been appointed as a Non-Executive Director of Genetic Signatures Limited with immediate effect.

The Board welcomes Mr Melki and looks forward to working with him as the Company continues to focus on delivering value for shareholders.

In accordance with ASX Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth), details of the resolutions and proxy and poll voting results are attached to this announcement.

An Appendix 3X (Initial Director's Interest Notice) for Mr Melki will follow separately.

This announcement has been authorised for release by the Board of Directors of Genetic Signatures Limited.

– END –

For further information, see our website (www.geneticsignatures.com) or contact us:

Sonya Tissera
Company Secretary
Genetic Signatures Limited

About Genetic Signatures

Genetic Signatures is a specialist molecular diagnostics company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen™ brand. Genetic Signatures' proprietary 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.

Genetic Signatures Limited
General Meeting
Wednesday, 28 October 2026
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1. Appointment of Susan Margaret Forrester as a Director	Ordinary	52,130,367 35.08%	94,537,774 63.62%	1,937,878 1.30%	1,004,065	52,318,793 35.16%	96,475,652 64.84%	1,871,653	Not Carried
		50 17.36%	238 82.64%					4	
2. Removal of Michael Aicher as a Director	Ordinary	71,052,649 47.81%	75,613,341 50.88%	1,939,029 1.30%	1,005,065	71,363,198 47.96%	77,430,247 52.04%	1,872,653	Not Carried
		54 18.95%	231 81.05%					5	
3. Appointment of John Robert Melki as a Director	Ordinary	103,815,869 70.51%	41,485,052 28.17%	1,943,285 1.32%	2,365,878	104,994,006 70.80%	43,306,214 29.20%	2,365,878	Carried
		174 61.05%	111 38.95%					4	
4. Removal of Dr Jenny Harry as a Director	Ordinary	48,108,836 32.53%	97,852,494 66.16%	1,940,029 1.31%	1,708,725	48,250,977 32.58%	99,838,808 67.42%	2,576,313	Not Carried
		34 11.97%	250 88.03%					8	

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.